Black Diamond Therapeutics

Investment decisions are made by the board of directors and executive management, led by CEO Mark Velleca. Because Black Diamond is a publicly traded biotech company rather than a family office or fund, capital allocation flows through traditional corporate governance — the board approves major financial commitments, while the executive team determines clinical and research spending priorities. The March 2025 debt facility with Perceptive Advisors was a board-authorized capital-raising decision.

The Mutation-Allostery-Pharmacology platform computationally maps every known oncogenic mutation across a protein family, then screens for small molecules that bind to allosteric sites — pockets distinct from the active site most kinase inhibitors target. This matters because resistance mutations that defeat active-site binders often leave allosteric pockets intact. The platform gives Black Diamond a way to pursue targets like EGFR and KRAS that have already been validated commercially but where treatment resistance creates a recurring need for new chemical matter.

The lead program, BDTX-1535, is a fourth-generation EGFR inhibitor in a Phase 2 trial for recurrent glioblastoma and a Phase 1/2 trial for non-small cell lung cancer with acquired resistance mutations. BDTX-4933, targeting RAF-mutant solid tumors, is also in clinical trials. Preclinical programs include KRAS inhibitors aimed at mutations beyond the G12C variant that Amgen's Lumakras and Mirati's Krazati address. The pipeline concentrates on validated oncogenic drivers where existing drugs fail due to specific resistance mutations.

Black Diamond Therapeutics is a clinical-stage biotechnology company, not a family office or investment firm. It operates as a publicly traded corporation on Nasdaq under the ticker BDTX. It deploys its capital entirely into its own research and clinical development programs rather than into external portfolio companies or fund commitments.

Versant Ventures co-founded the company in 2015. The public shareholder base includes institutional investors typical of a development-stage biotech. In March 2025, healthcare-focused investment firm Perceptive Advisors provided a debt facility of up to $250 million, which gives the company non-dilutive capital to extend its clinical development runway. Early investors also included venBio and Nextech Invest as venture backers.

Research operations are headquartered in Cambridge, Massachusetts. The company's clinical trials enroll patients at oncology centers across the United States, with key investigative sites historically including Dana-Farber Cancer Institute in Boston and Memorial Sloan Kettering in New York. The glioblastoma and lung cancer trials are designed as multi-center US studies, with potential expansion sites in other countries depending on enrollment needs.

Most oncology biotechs pursue a single validated target or a basket of tumors sharing a genetic marker. Black Diamond pursues a family of mutationally defined protein targets, using the MAP platform to screen across all known oncogenic drivers in 50 kinase families. This creates an unusual pipeline structure: rather than building a single drug for a single cancer, the company builds a discovery engine that generates inhibitors against whichever mutations emerge as clinically relevant, effectively pre-positioning for the next wave of resistance-driven patient populations.